Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Black-Box Warning for Cilta-Cel Over Secondary Blood Cancers
The FDA has issued an update to the ciltacabtagene autoleucel (CARVYKTI) label describing secondary AML/MDS in 10% of patients treated on CARTITUDE-1 (10/97). CARTITUDE-1 is a Phase IB/II trial that evaluated ciltacabtagene autoleucel (CARVYKTI) in patients with relapsed of refractory…
